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Abstract
Background: This study characterized the landscape of commercially available medical devices specifically
designed for use in low-income countries (LICs).
Methods: A state-of-the-art review of peer-reviewed publications, patents, global health databases, and online
resources was performed. The criteria established for a health technology’s inclusion in the study were: it met the
definition of a medical device; it was designed and developed to address one of the top ten causes of death in
LICs, Millennium Development Goal (MDG) 4, or MDG 5; and there was evidence of its commercialization.
Results: Analysis identified 134 commercialized devices exclusively designed for use in LICs. More than 85% of
devices were designed to address infectious diseases or child or maternal health (MDG 4 or 5, respectively). None
of the identified devices addressed prevention of noncommunicable diseases (NCDs). Only 8% of devices were
designed for use in primary health facilities by non-physician health providers.
Conclusion: There is a significant mismatch between the projected global burden of disease due to NCDs and the
relevant number of commercialized medical devices designed specifically for use in LICs. A limited number of
commercialized devices were designed for use by non-physician health providers. These findings suggest the
need for medical devices targeting NCDs in LICs and design processes that consider the broader context of
design and engage stakeholders throughout all phases of design.
Keywords: Global health, Health technology, Low-income countries, Medical devices, Noncommunicable diseases,
Primary health care facilities
Background
The availability, accessibility, and effectiveness of medical
devices are vital in achieving the highest quality of care
within health systems [1]. Medical devices, defined as “ar-
ticles, instruments, apparatus, or machines that are used
in the prevention, diagnosis, or treatment of illness or dis-
ease, or for detecting, measuring, restoring, correcting, or
modifying the structure or function of the body for some
health purpose” [2], are a major part of health technolo-
gies (which also include vaccines and medicines), and an
essential building block in any functioning health system
[1]. The World Health Organization (WHO) indicates
that there are over 10,000 types and brands of medical de-
vices globally, ranging from basic stethoscopes to complex
diagnostic imaging machines; it estimated that the global
medical devices market was over $350 billion in 2011 [3].
However, historically, the overwhelming majority (~ 90%)
of health technology sales have occurred within high- and
middle-income countries [3, 4].
Almost 80% of medical devices in LICs are acquired
by donation [5]. In addition to donations, medical de-
vices are also acquired through technology transfer: local
production of devices that resemble technology designed
for use in high-income countries (HICs) or the low-cost
sale of older models of devices originally designed for
use in HICs [5, 6]. However, use of medical devices in
LICs that were originally designed for use in HIC are
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not entirely successful; one study noted that 40% of med-
ical devices were dysfunctional in LICs versus less than 1%
in HICs [6, 7]. In LICs, constraints including unreliable
energy supply and water, limited distribution and infra-
structure, inadequate or untrained workforces, lack of
spare parts, required consumables, and high costs affect
the availability and acceptability of many devices [8].
Decades of investing in lifesaving medical devices,
training health care providers at various levels, and plan-
ning strategic interventions globally have led to drastic
reductions in mortality due to infectious diseases, mater-
nal and child illness, and malnutrition [9]. While infec-
tious diseases have been in the spotlight for the last few
decades, noncommunicable diseases (NCDs) accounted
for 63% of global deaths in 2008–80% of which occurred
in low- and middle-income countries (LMICs) [10]. In
fact, deaths from NCDs were projected to increase to 52
million by 2030, with NCDs in LMICs responsible for
three times as many disability-adjusted life years
(DALYs) and nearly five times as many deaths as infec-
tious diseases, maternal, perinatal, and nutritional condi-
tions combined [10]. Given these projections, the WHO
and the UN called for “25 by 25”, i.e., a 25% reduction in
the mortality caused by NCDs among individuals be-
tween 30 and 70 years of age by 2025 [11, 12].
Even though the role of medical devices in addressing
pressing global health challenges is widely acknowl-
edged, the landscape of commercialized medical devices
specifically designed for LICs is unknown [3]. For in-
stance, it is essential to know the availability of devices
to address NCDs, and to evaluate the number of devices
designed for use by non-physician health providers,
given the limited number of highly trained human re-
sources in LICs (47% of the WHO member states re-
ported having less than 1 physician per 1000 population
[13]). This research characterizes the current landscape
of commercialized medical devices that are specifically
designed for use in LICs.
Methods
A state-of-the-art review [14] was conducted by a team
of 30 research assistants from the University of Michigan
to identify health technologies designed to address at
least one of the top ten causes of death, UN Millennium
Development Goal (MDG) 4 (reduce child mortality), or
MDG 5 (improve maternal health) in LICs. The research
team searched online data only. The information sources
included the WHO’s compendium of innovative
health technologies for low-resource settings [15] and
MANDATE’s technology assessment tool [16]. Also,
peer-reviewed, published articles and patent applications
were identified using PubMed, Google Scholar, and the
US Patent and Trademark Office database. Keywords used
to identify devices included, but were not limited to, the
following terms, individually or in combination: medical
devices, health technology, frugal design, engineering de-
sign, global health, low-income countries, low- and
middle-income countries. Names of specific health chal-
lenges (e.g., cancer) in conjunction with other keywords
were also used as search terms.
Following a general search for health technologies
meeting these preliminary criteria, a subset of the identi-
fied health technologies was classified as medical devices
and considered for this study based on the following in-
clusion criteria:
1. Met the definition of a medical device [2], and
2. Designed specifically to address a health challenge
in LICs, based on the intentions expressed by the
developer of the medical device, and
3. Supplied evidence to support the commercialization
(i.e., available and accessible to end-users in target
settings [17]) of the device in LICs.
A template was developed to systematically compile in-
formation about each identified device including scope
(diagnostic, prevention, and treatment), stage (concept,
clinical trial, commercialized), developer, testing and im-
plementation details, funding sources, and references. Cat-
egorizing the devices by scope and stage allowed for
additional analysis on the number of available devices.
The data for devices selected for inclusion were then
reviewed for accuracy and assessed for bias by two study
team members.
The data collected during this study were subsequently
included in an online, collaborative, open-access plat-
form, known as the Compendium of Medical Devices
for Global Health [18]. This information is currently
available for public access. The findings and interpret-
ation presented here are based on the data collected be-
tween January 15, 2010 and December 31, 2013.
Results
The initial search identified 401 health technologies, in-
clusive of medical devices, mHealth solutions, and vac-
cines, intended for use in LICs. The subsequent
classification process resulted in the identification of 358
medical devices of which 134 (37% of total) met the
“commercialization” criterion (inclusion criteria #3) to
address specific health topics in LICs. One imaging de-
vice was double-counted because it is used for both ma-
ternal and infant health. The remaining 224 devices
were either at the early concept (prototype) design stage
or at the clinical trial stage. Fig. 1 shows the number of
devices developed per health topic, clustered based on
their associated scope (i.e., diagnostic, prevention, and
treatment), and mortality projections for infectious diseases,
NCDs, pregnancy-related complications, and newborn
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conditions in LICs [19]. Of the total 134 commercialized
devices, 114 (85%) targeted infectious diseases or MDG 4
or MDG 5. The HIV/AIDS topic had the largest number of
commercialized devices (36), with the majority in the diag-
nostic category (31). There was one commercialized device
for the respiratory infections topic and only one for the
cancer topic. Other than for the waterborne diseases topic,
there was only one device-based treatment for infectious
diseases.
Only 20 commercialized medical devices (< 15%) were
identified to address NCDs, revealing a significant mis-
match between the number of commercialized devices
and the increasing global burden of NCDs. For instance,
fewer than 10 devices addressed cardiovascular diseases
and cancer in LICs, whereas the annual cardiovascular
disease mortality was projected to increase by 6 million
and the number of annual cancer deaths by 4 million
over the next 20 years in LICs [19]. Notably, none of the
Fig. 1 The left side bar graphs show the actual (2005) and projected (2015 and 2030) mortality in LICs [19]. The right side bar graphs show the
commercialized medical devices designed to address one of the top 10 causes of death or MDG 4 or MDG 5 in LICs. Devices are categorized
based on the health problem addressed and their scope
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identified devices were designed for the prevention of
NCDs. Vscan (Fig. 2a), a pocket-size, portable, and low-
cost ultrasound machine is an example of a medical de-
vice that has been designed and commercialized consid-
ering the specific needs of LICs [20].
Among the identified devices, only 30 were commer-
cialized for use at the primary health care level, which
are typically staffed by non-physician health care pro-
viders, and none addressed any of the NCDs. LifeWrap, a
fully mechanical device used to control postpartum
hemorrhage (Fig. 2b), a leading cause of global maternal
mortality [21], and Uniject™, an auto-disable injection de-
vice used to deliver vaccines and drugs (Fig. 2c) [22] are
examples of medical devices designed for use by non-
physician health care providers. These devices are notable
because they are relatively easy to learn how to use, do
not require consumables, and do not rely on electricity.
From the analysis, 55 commercialized devices were
powered mechanically and another 52 devices (mostly
diagnostic) employed a chemical reaction, suggesting
that approximately 80% did not rely on electricity as a
power source.
Discussion
Medical devices have a limited, yet important role in the
effective delivery of health care [3]. The role of medical
devices and health technology in the fight against NCDs
was emphasized in the Global Action Plan for the Pre-
vention and Control of NCDs proposed by the WHO
and endorsed by the World Health Assembly in 2013
[23]. However, the evident mismatch between the num-
ber of commercialized medical devices, which are specif-
ically designed for and accessible in LICs, and the
projected burden of diseases due to NCDs in LICs is of
concern. Even though NCDs are projected to represent
the greatest burden on health in the near future, the
number of medical devices designed and commercialized
to prevent, diagnose, and treat physical disability, cardio-
vascular diseases, diabetes mellitus, road traffic acci-
dents, and cancer combined is considerably smaller than
the number designed and commercialized to prevent,
diagnose, and treat infectious diseases, maternal
health, and infant health.
There is a critical gap between designing and develop-
ing a safe and effective medical device and implementing
and scaling that device within the target setting [7]. The
total number of concept solutions, early stage proto-
types, and low-scale medical devices aimed at addressing
global health challenges greatly exceeds the number of
medical devices included in this study. Among the hun-
dreds of medical devices designed to be low cost and
contextually appropriate that were not included, many
likely failed to reach scale because they did not effectively
address an unmet need, lacked established pathways to
facilitate the transition from technical designers to orga-
nizations or individuals skilled in implementation and
commercialization of technology, lacked adequate fund-
ing, encountered challenges navigating regulatory path-
ways or securing appropriate intellectual property, or
insufficiently managed the supply chain (e.g., procure-
ment, distribution, maintenance) [7, 24, 25]. Overcoming
Fig. 2 a Vscan used in a health post in sub-Saharan Africa (image
from http://www.gesustainability.com); b LifeWrap applied on a
woman (image from http://www.lifewraps.org); c Uniject™ (image
from http://www.path.org)
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the complexities associated with implementing and scaling
a medical device may require modeling and simulation of
scale-up, creation of effective delivery mechanisms, pur-
suit of novel financing, and implementation of evidence-
based operational practices [7, 26].
The lack of medical device maintenance, a significant
challenge to health systems in LICs, negatively impacts
patient care and public health [27]. Factors affecting the
maintainability of medical devices include shortages of
trained biomedical technicians, limited access to spare
parts and consumables, and infrastructural constraints
such as consistent power availability [27]. From a design
perspective, inclusion of only essential functions, reduc-
tion of the number of custom components, and incorp-
oration of maintenance and troubleshooting aids can
improve the maintainability of medical devices [7]. From
a health care system perspective, the practice of pre-
ventative maintenance can extend the useful lifetime of
medical devices [27], and local production can increase
the likelihood of locally available product support and
the availability of medical device consumables [7].
Successful design for LICs also depends on understand-
ing the broader issues associated with implementation in
the early stages of the development process rather than
after the validation and production stages [28, 29]. For ex-
ample, considerations regarding medical device
commercialization and adoption are likely to be different in
LICs [25]. Therefore, novel medical device design frame-
works that consider downstream variables (e.g., manufac-
turing plans, regulatory pathways, etc.) as well as the
broader context during the front-end phases of design (e.g.,
development of product requirements and technical specifi-
cations) are needed [28]. Design approaches that consider
local and regional constraints, cultural contexts, and stake-
holder needs, and enhance the capacity of the local health
care workforce are particularly effective [6, 8].
The limited availability of highly trained health pro-
viders presents an extraordinary challenge in providing
universal quality care. For instance, while Africa bears
more than 24% of the global burden of disease, it only
has access to 2% of the global physician supply [30].
Therefore, non-physician health care providers such as
community health workers have the potential to extend
access to essential health services, particularly in rural
settings within LICs [31]. Task-shifting promotes the ef-
ficient use of available human resources by transferring
appropriate tasks typically performed by “highly qualified
health workers to health workers with shorter training
and fewer qualifications” [32]. To date, limited medical
devices have been designed specifically for task-shifting
applications; such devices can play a critical role in im-
proving access to universal care and tackling the threat
of NCDs, particularly in rural LICs. Devices that are easy
to use, have limited components, no need for spare
parts, minimal to no maintenance or need for calibra-
tion, and use reliable and readily available energy sources
may increase their suitability for community health
workers performing task-shifting duties [28].
Study limitations included the possible omission of
relevant medical devices due to online information that
was insufficient, not found, or not in English. Descrip-
tions and information used to classify the identified
medical devices were limited by the information pro-
vided by the device designers and developers, and other
available online sources, and the study team did not in-
dependently evaluate and validate these claims. This
study solely focused on identifying medical devices de-
signed for and commercialized in LICs. Of course there
are other devices used in these settings that might not
fit the inclusion criteria, but are still effective in address-
ing health challenges. The focus on actual and projected
mortality due to infectious diseases, NCDs, pregnancy-
related complications, and newborn conditions in LICs
did not consider the DALYs, a limitation which poten-
tially could skew the outcomes, since some devices could
have improved the life conditions of affected individuals
(projected as DALYs).
Conclusions
The magnitude of the NCD epidemic illustrates the need
for targeted medical device development, considering the
context and end-user environment of use. The mismatch
between the number of commercially available medical
devices and the projected global burden of disease, as well
as the limited number of available devices designed for
use by community health workers to support task-shifting
will require policymakers and the global health commu-
nity to provide intellectual, financial, and regulatory sup-
port in order to develop the necessary technology in a
timely manner. Although it is not possible to separate the
effects of global health technologies, in this case, medical
devices for LICs, from the effects of social, political, eco-
nomical, and healthcare measures on mortality in LICs
[7], availability and accessibility of medical devices are im-
portant and if part of a comprehensive solution, can posi-
tively impact global mortality and morbidity trends.
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